NEWPORT BEACH, CA, VivoSense an agile end-to-end scientific solutions company, announced the close of a $25 Million Series A financing round.
VivoSense an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data, announced the close of a $25 Million Series A financing round.
Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
